Through Purdue’s new life sciences initiative, we are harnessing our life sciences expertise and state-of-the-art facilities to tackle some of the world’s most debilitating and deadly diseases and to help feed a growing world population.
- Integrate cross-campus, neurological and immunological sciences faculty in focused interdisciplinary research environments to advance neuroscience, immunology, inflammation and infectious disease research.
- Expand Purdue’s contribution to the national neuroscience and immunological sciences effort.
- Attract new faculty in neuroscience and immunological sciences, and strengthen the interface between biology and engineering.
- Create new technologies to enhance the detection and treatment of human disease.
- In January 2016, Purdue announced an investment of more than $250 million in the life sciences over five years to advance life science research that both improves lives and supports Indiana’s critical life sciences business sector.
- In the last three years, we have launched two new interdisciplinary campus-wide institutes — the Purdue Institute of Inflammation, Immunology and Infectious Disease (PI4D) and the Purdue Institute for Integrative Neuroscience (PIIN) — to complement existing research centers on cancer, health-care engineering, drug discovery and plant science.
- Established the Neuroscience Cell Engineering Core in the PIIN.
- We also have added new core research facilities, garnered millions of dollars in new grants and private donations, helped to fund new startups, recruited new faculty members, and expanded partnerships with leading universities and life science companies.
- Purdue has expanded partnerships with leading universities and life science companies, including:
- A strategic alliance with the Indiana Biosciences Research Institute (IBRI) to promote fundamental research in Indiana that will strengthen the state’s life sciences industries
- A growing partnership with the Jordan University of Science and Technology (JUST) to establish the Regional Center for Infectious Diseases and Antimicrobial Resistance at JUST to reduce the threat of infectious diseases, emerging diseases and antibiotic resistance that increasingly has become a serious global issue.
- Purdue researchers were the first in the world to map the structure of the Zika virus and continue to lead the way in critical Zika research, reaching breakthroughs such as understanding how it effects the brain and paving the way for vaccine design.
- In June 2018, Purdue researchers announced the identification of a new compound, F6, that is as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections such as methicillin-resistant Staphylococcus aureus (MRSA), while also appearing to be less susceptible to bacterial resistance — critical at a time when antibiotic resistance is a growing public health crisis.
- In May 2018, Purdue researchers announced the release of two new smartphone apps: one that allows a typical smartphone to analyze produce for foodborne pathogens such as E. coli and one that helps pregnant women detect whether they have or are susceptible to preeclampsia.